Xellar Biosystems Raises $50M Series A for AI Drug Discovery

July 8, 2026

Fundraise Insider tracks newly funded startups each week and delivers verified B2B leads list of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.

Xellar Biosystems, a biotech company based in Newton, Massachusetts, has closed $50 million in Series A and A+ financing to advance its drug discovery platform. The company announced the round on June 29, 2026.

Founded in 2022, Xellar builds what it calls 3D Bio Intelligence, an approach that pairs organ on a chip technology with advanced imaging and machine learning to speed up how new drugs are found and developed.

The platform combines wet lab experiments with AI models to make sense of complex biological data, with the aim of cutting the time and cost of moving new treatments forward.

The financing gives Xellar more room to grow its platform as investor interest holds up in tools that use computation to make drug research faster and more predictable.

You may also like

35 Sales Email Tips to Crush Your Sales Game

In today’s digital age, email remains one of the most effective tools for reaching out to potential customers and driving sales. However, crafting a successful sales email can be tricky, as you need […]

Recently Funded Startups Are A Great Sales Target. Here’s Why.

The startup industry has been growing at an unprecedented rate in recent years, with billions of dollars being poured into the sector every year. This growth has created an opportunity for businesses to […]

How to Identify Your B2B Target Audience: A Comprehensive Guide

For any business to succeed, it is essential to target the right audience. In B2B marketing, identifying your target audience is even more important, as it helps you focus your efforts and resources […]